Key Insights:
- Novavax (NVAX, Financial) saw a 23% stock price decline after comments from US Health Secretary Robert Kennedy Jr.
- Wall Street analysts foresee a potential upside of over 219% with price targets as high as $25.
- The GF Value indicates a potential downside of 8.2%, highlighting a possible overvaluation.
Novavax (NVAX) experienced a sharp 23% drop in its stock price, a significant market reaction triggered by US Health Secretary Robert Kennedy Jr.'s comments, which raised doubts about the effectiveness of its Covid-19 vaccine. Currently, Novavax's Nuvaxovid vaccine holds conditional approval as it awaits full FDA approval, anticipated by April 1.
Wall Street Analysts' Price Targets
Wall Street analysts have provided one-year price targets for Novavax Inc (NVAX, Financial), with an average target price set at $17.33. This average represents a substantial upside of 219.51% from the current trading price of $5.43. These predictions range from a high of $25.00 to a low estimate of $9.00. For more in-depth projections, visit the Novavax Inc (NVAX) Forecast page.
Brokerage Recommendations
The consensus from seven brokerage firms places Novavax Inc (NVAX, Financial) at an average recommendation of 2.3, which signifies an "Outperform" rating. On the scale used, 1 corresponds to a Strong Buy and 5 to a Sell, indicating a favorable outlook among analysts.
GF Value Assessment
According to GuruFocus estimates, the GF Value for Novavax Inc (NVAX, Financial) one year from now is $4.98. This suggests a potential downside of 8.2% from the current price of $5.425, marking a note of caution for investors. The GF Value provides an estimate of the stock's fair trading value, calculated based on historical trading multiples, business growth trends, and future business performance estimates. For a more comprehensive analysis, see the Novavax Inc (NVAX) Summary page.
